Stable transplantation of human mitochondrial DNA by high-throughput, pressurized isolated mitochondrial delivery

  1. Alexander J Sercel
  2. Alexander N Patananan
  3. Tianxing Man
  4. Ting-Hsiang Wu
  5. Amy K Yu
  6. Garret W Guyot
  7. Shahrooz Rabizadeh
  8. Kayvan R Niazi
  9. Pei-Yu Chiou
  10. Michael A Teitell  Is a corresponding author
  1. UCLA, United States
  2. NanoCav, LLC, NantBio, Inc, and ImmunityBio, Inc, United States
  3. NanoCav, LLC, NantBio, Inc, and ImmunityBio, Inc, and NantOmics, LLC, United States

Abstract

Generating mammalian cells with specific mtDNA-nDNA combinations is desirable but difficult to achieve and would be enabling for studies of mitochondrial-nuclear communication and coordination in controlling cell fates and functions. We developed 'MitoPunch', a pressure-driven mitochondrial transfer device, to deliver isolated mitochondria into numerous target mammalian cells simultaneously. MitoPunch and MitoCeption, a previously described force-based mitochondrial transfer approach, both yield stable isolated mitochondrial recipient (SIMR) cells that permanently retain exogenous mtDNA, whereas coincubation of mitochondria with cells does not yield SIMR cells. Although a typical MitoPunch or MitoCeption delivery results in dozens of immortalized SIMR clones with restored oxidative phosphorylation, only MitoPunch can produce replication-limited, non-immortal human SIMR clones. The MitoPunch device is versatile, inexpensive to assemble, and easy to use for engineering mtDNA-nDNA combinations to enable fundamental studies and potential translational applications.

Data availability

Figure 1-source data 1. Numerical simulation of MitoPunch pressure generation during mitochondrial delivery. Cited in the legend of Figure 1.

Article and author information

Author details

  1. Alexander J Sercel

    Molecular Biology Institute Interdepartmental Program, UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  2. Alexander N Patananan

    Pathology and Laboratory Medicine, UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  3. Tianxing Man

    Mechanical and Aerospace Engineering, UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  4. Ting-Hsiang Wu

    NanoCav, LLC, NantBio, Inc, and ImmunityBio, Inc, Culver City, United States
    Competing interests
    Ting-Hsiang Wu, T.-H.W. was an employee of NanoCav, LLC, and is currently employed by NantBio, Inc and ImmunityBio, Inc..
  5. Amy K Yu

    Molecular Biology Institute Interdepartmental Program, UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  6. Garret W Guyot

    Pathology and Laboratory Medicine, UCLA, Los Angeles, United States
    Competing interests
    No competing interests declared.
  7. Shahrooz Rabizadeh

    NanoCav, LLC, NantBio, Inc, and ImmunityBio, Inc, and NantOmics, LLC, Culver City, United States
    Competing interests
    Shahrooz Rabizadeh, S.R. is a board member of NanoCav, LLC, and employed by NantBio, Inc, ImmunityBio, Inc, and NantOmics, LLC..
  8. Kayvan R Niazi

    NanoCav, LLC, NantBio, Inc, and ImmunityBio, Inc, Culver City, United States
    Competing interests
    Kayvan R Niazi, K.R.N. is a board member of NanoCav, LLC, and employed by NantBio, Inc and ImmunityBio, Inc..
  9. Pei-Yu Chiou

    Mechanical and Aerospace Engineering, UCLA, Los Angeles, United States
    Competing interests
    Pei-Yu Chiou, P.-Y.C. is a co-founder, board member, shareholder, and consultant for NanoCav, LLC, a private start-up company working on mitochondrial transfer techniques and applications..
  10. Michael A Teitell

    Pathology and Laboratory Medicine, UCLA, Los Angeles, United States
    For correspondence
    mteitell@mednet.ucla.edu
    Competing interests
    Michael A Teitell, M.A.T. is a co-founder, board member, shareholder, and consultant for NanoCav, LLC, a private start-up company working on mitochondrial transfer techniques and applications..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4495-8750

Funding

National Institutes of Health (T32CA009120)

  • Alexander J Sercel
  • Alexander N Patananan

National Institutes of Health (R21CA227480)

  • Michael A Teitell

National Institutes of Health (P30CA016042)

  • Michael A Teitell

CIRM (RT3-07678)

  • Michael A Teitell

National Institutes of Health (T32GM007185)

  • Alexander J Sercel

American Heart Association (18POST34080342)

  • Alexander N Patananan

National Institutes of Health (T32GM008042)

  • Amy K Yu

National Science Foundation (CBET 1404080)

  • Pei-Yu Chiou

National Institutes of Health (R01GM114188)

  • Pei-Yu Chiou
  • Michael A Teitell

Air Force Office of Scientific Research (FA9550-15-1-0406)

  • Pei-Yu Chiou
  • Michael A Teitell

National Institutes of Health (R01GM073981)

  • Michael A Teitell

National Institutes of Health (R01CA185189)

  • Michael A Teitell

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Sercel et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,063
    views
  • 470
    downloads
  • 29
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alexander J Sercel
  2. Alexander N Patananan
  3. Tianxing Man
  4. Ting-Hsiang Wu
  5. Amy K Yu
  6. Garret W Guyot
  7. Shahrooz Rabizadeh
  8. Kayvan R Niazi
  9. Pei-Yu Chiou
  10. Michael A Teitell
(2021)
Stable transplantation of human mitochondrial DNA by high-throughput, pressurized isolated mitochondrial delivery
eLife 10:e63102.
https://doi.org/10.7554/eLife.63102

Share this article

https://doi.org/10.7554/eLife.63102

Further reading

    1. Cell Biology
    Joan Chang, Adam Pickard ... Karl E Kadler
    Research Article

    Collagen-I fibrillogenesis is crucial to health and development, where dysregulation is a hallmark of fibroproliferative diseases. Here, we show that collagen-I fibril assembly required a functional endocytic system that recycles collagen-I to assemble new fibrils. Endogenous collagen production was not required for fibrillogenesis if exogenous collagen was available, but the circadian-regulated vacuolar protein sorting (VPS) 33b and collagen-binding integrin α11 subunit were crucial to fibrillogenesis. Cells lacking VPS33B secrete soluble collagen-I protomers but were deficient in fibril formation, thus secretion and assembly are separately controlled. Overexpression of VPS33B led to loss of fibril rhythmicity and overabundance of fibrils, which was mediated through integrin α11β1. Endocytic recycling of collagen-I was enhanced in human fibroblasts isolated from idiopathic pulmonary fibrosis, where VPS33B and integrin α11 subunit were overexpressed at the fibrogenic front; this correlation between VPS33B, integrin α11 subunit, and abnormal collagen deposition was also observed in samples from patients with chronic skin wounds. In conclusion, our study showed that circadian-regulated endocytic recycling is central to homeostatic assembly of collagen fibrils and is disrupted in diseases.

    1. Cell Biology
    Chun-Wei Chen, Jeffery B Chavez ... Bruce J Nicholson
    Research Article Updated

    Endometriosis is a debilitating disease affecting 190 million women worldwide and the greatest single contributor to infertility. The most broadly accepted etiology is that uterine endometrial cells retrogradely enter the peritoneum during menses, and implant and form invasive lesions in a process analogous to cancer metastasis. However, over 90% of women suffer retrograde menstruation, but only 10% develop endometriosis, and debate continues as to whether the underlying defect is endometrial or peritoneal. Processes implicated in invasion include: enhanced motility; adhesion to, and formation of gap junctions with, the target tissue. Endometrial stromal (ESCs) from 22 endometriosis patients at different disease stages show much greater invasiveness across mesothelial (or endothelial) monolayers than ESCs from 22 control subjects, which is further enhanced by the presence of EECs. This is due to the enhanced responsiveness of endometriosis ESCs to the mesothelium, which induces migration and gap junction coupling. ESC-PMC gap junction coupling is shown to be required for invasion, while coupling between PMCs enhances mesothelial barrier breakdown.